Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Diabetes Health Center

Font Size

FDA Panel Splits Over Avandia Ban

20-12 Vote to Strengthen Avandia Warning, but Many Panelists Want Ban

Critics: Avandia Clinical Trial Unethical continued...

That's because the FDA itself is split over the Avandia question. The split is over a philosophical question: Should safety concerns take priority, or should the FDA focus on the need of patients (and drugmakers) for new treatments?

It's not an easy question, especially as the Avandia controversy has called into question the quality of data submitted to the FDA. Avandia maker GlaxoSmithKline has come under fire for hiding unfavorable data on Avandia and for irregularities in handling and interpreting clinical trial data.

The panel also voted:

  • 18-6 that available data suggest Avandia increases heart attack risk more than do other classes of diabetes drugs. Nine panelists said they did not have enough data to decide.
  • 21-3 that available data suggest Avandia increases heart attack risk more than does Actos. Nine panelists said they did not have enough data to decide.
  • 21-1 that there is not enough data to show that Avandia increases risk of death more than other classes of diabetes drugs. Eleven panelists said they did not have enough data to decide.

The panel also voted 19-11 to continue with a clinical trial, nicknamed TIDE, comparing Avandia to Actos. Critics of the study say the trial is unethical, as it is basically asking patients to take Avandia to see if it harms them. But most panelists, frustrated by two days of inconclusive study presentations, want to see some answers -- even if it takes years.

Oddly, panel members who voted to ban Avandia voted to continue the TIDE trial. One such panelist was Marvin Konstam, MD, professor of cardiology at Tufts University, Boston.

"The panel vote was to leave the drug on the market, and so we will need this study," Konstam said. "You need to inform the patient enrolled in the trial that the only reason Avandia is in the study is to see if it harms you. That is a problem."

1 | 2

Today on WebMD

Diabetic tools
Symptoms, diagnosis, treatment, and more.
woman flexing muscles
10 strength training exercises.
Blood sugar test
12 practical tips.
Tom Hanks
Stars living with type 1 or type 2.
kenneth fujioka, md
Can Vinegar Treat Diabetes
Middle aged person
Home Healthcare

Prediabetes How to Prevent Type 2 Diabetes
type 2 diabetes
food fitness planner